NASDAQ:FULC

Fulcrum Therapeutics Earning Date

USA |NASDAQ |USD

FULC Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 8, 2021 Sep 2021 $-0.65 $-0.60 $-0.70
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 8, 2021 Sep 2021 $2.25M $4.38M $1.85M

Fulcrum Therapeutics's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.

FULC Earnings Date & History Chart

FULC Earnings & Revenue Forecast

FULC Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 7 $-0.80 $-1.05 $-0.55
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $-2.61 $-3.08 $-2.27
Dec 2022 7 $-2.72 $-3.41 $-2.26

FULC Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.80 $-0.78 $-0.80
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-2.61 $-2.52 $-2.63
Dec 2022 0 / 0 $-2.72 $-2.92 $-2.79

FULC Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 5 $2.35M $0.00 $4.00M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 7 $11.35M $0.00 $17.20M
Dec 2022 7 $12.60M $0.00 $27.00M

FULC Earnings Date & Revenue History

FULC Earnings History

|
Show More
Show More

FULC Revenue History

|
Show More
Show More

Fulcrum Therapeutics Next Earnings Date & Report

FULC Next Earnings Date & Report Preview: Sep 2021 (FQ)

FULC's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 7 analysts, the average EPS estimation for Fulcrum Therapeutics's next quarterly earnings is $-0.65, with a low EPS estimation of $-0.74, and a high estimation of $-0.57.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.65, the last 2 month trend is $-0.63, and the 3 month trend is $-0.65.

Based on 6 analysts, the average revenue estimation is $2.25M, with a low revenue estimation of $0.00, and a high estimation of $4.00M.

Fulcrum Therapeutics Previous Earnings Dates & Reports

FULC Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Fulcrum Therapeutics's previous earnings date was Aug 10, 2021 for its fiscal quarter ended Jun 30, 2021.

FULC's earnings per share (EPS) was $-0.60, beating the consensus analysts forecast of $-0.65 by 8.10%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 11.11%, and higher than the same period a year before (Jun 2020) by -9.09%.

Revenues were $4.38M, better than the forecast of $1.60M by 173.81%, down by -8.52% from the previous quarter , and up by 119.05% from the same period last year.

The company reported a net income of $-19.65M.

Free cash flow for the quarter was $-18.39M , compared to $-16.49M last quarter and $-14.33M a year before.

FULC ended the quarter with $469.00K in total debt, an increase of 11625.00% compared to the previous quarter, and an increase of 990.70% compared to the same quarter a year before.

FULC Previous Earnings Date & Report Recap: Dec 2020 (FY)

Fulcrum Therapeutics's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.

FULC's earnings per share (EPS) was $-2.80, beating the consensus analysts forecast of $-2.88 by -2.78% , and lower than the previous year's EPS (Dec 2019) by 17.15%.

Revenues were $8.82M.

The company reported a net income of $-70.82M.

Fulcrum Therapeutics reported a free cash flow of $-55.00M for its fiscal year, compared to $-40.34M a year ago.

The company ended the fiscal year with $17.00K in total debt, a decrease of -66.00% compared to the previous year.